Insilico Medicine has started a Phase 1 trial of ISM6331, a new pan-TEAD inhibitor, on its first patient. This drug could be a breakthrough for mesothelioma and other solid tumors. Mesothelioma is a rare and aggressive cancer that usually shows up in the lining of the lungs, abdomen, heart, or testicles.
It is often called the “Silent Killer” because it is hard to treat and has low survival rates. ISM6331 offers new hope for patients with this deadly disease. What makes ISM6331 special is that it was designed using artificial intelligence (AI).
Instead of the traditional trial and error method that can take years or decades, Insilico Medicine used algorithms and deep learning to create a molecule that could potentially fight cancer perfectly. Insilico also got Orphan Drug Designation (ODD) from the FDA for ISM6331. This gives the company regulatory benefits, tax breaks, and an advantage in bringing the drug to market.
The clinical trial is happening in both China and the United States at the same time. The first patient was given the drug in China, and enrollment in the U.S. is expected to increase quickly. However, there are current tensions between the two countries over AI technologies, intellectual property, and national security.
It remains to be seen if ISM6331 will be an example of global cooperation or become involved in the growing tech cold war. ISM6331 works by targeting the Hippo pathway, which is a key factor in the growth and survival of cancer cells.
Ai-designed cancer treatment insights
Studies before clinical trials showed that it has strong anti-tumor activity even at low doses and is safe in animal models. But promising results in the lab do not always mean success in clinical trials. Many hyped-up cancer drugs fail in Phase 1 because they do not work well enough or have unexpected side effects.
It is still unknown if ISM6331 will be a long-awaited breakthrough or follow the same path as other disappointing drugs. Insilico’s AI-driven approach is part of a bigger change in how the pharmaceutical industry develops new treatments. The company’s platform has already produced 22 preclinical candidates, with 10 molecules getting IND clearance.
In early 2024, Insilico published a study in Nature Biotechnology that explained the entire AI-driven process for its main drug, from creating the algorithm to Phase II trials. The big question is whether AI-designed drugs are really the future of medicine or just an overhyped trend. AI can make molecules faster than humans, but it cannot predict every possible side effect or guarantee long-term effectiveness.
If ISM6331 succeeds, it could prove that AI is a game-changer in drug discovery. But if it fails, it could set the whole industry back to the beginning. ISM6331 is one of the most closely watched clinical studies of the decade because it brings together AI, global politics, and high-stakes cancer research.
If Insilico succeeds, it could change the way we treat cancer and reshape the biotech industry. But science is full of “next big things” that never happen. Only time will tell if ISM6331 will be different or join the long list of medical breakthroughs that did not pan out.
Noah Nguyen is a multi-talented developer who brings a unique perspective to his craft. Initially a creative writing professor, he turned to Dev work for the ability to work remotely. He now lives in Seattle, spending time hiking and drinking craft beer with his fiancee.
